查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
脂質奈米顆粒製造的全球市場：服務與技術（按脂質奈米顆粒類型、供應分子類型、公司規模、目標治療領域、最終用戶、主要地區）：產業趨勢與全球預測（2023-2035） ）
市場調查報告書
商品編碼
1398316

脂質奈米顆粒製造的全球市場：服務與技術（按脂質奈米顆粒類型、供應分子類型、公司規模、目標治療領域、最終用戶、主要地區）：產業趨勢與全球預測（2023-2035） ）

Lipid Nanoparticle Manufacturing Market: Services & Technologies-Distribution by Type of Lipid Nanoparticle & Molecule Delivered, Company Size, Target Therapeutic Area, End-user, Key Geographical Regions: Industry Trends & Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 290 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2023年，全球脂質奈米顆粒製造市場規模將達6.6億美元，在預測期間（2023-2035年）複合年增長率為11.8%。

近年來，製藥業經歷了顯著擴張，臨床前和臨床試驗中批准或探索的藥物數量不斷增加就證明了這一點。 然而，藥物開發的一個持續障礙在於許多化合物的低水溶性和低生物利用度。 大約 90% 的正在開發的藥物和近 40% 的現有藥理製劑面臨溶解度和滲透性的挑戰。 這些問題通常在被吸收之前就離開了身體，從而影響了有效性。 因此，製藥公司正在積極尋求解決方案來克服這些障礙。 在提高治療藥物溶解度和生物利用度的各種策略中，類似脂質奈米顆粒（LNP）的脂質賦形劑引起了藥物開發商的極大關注。 LNP 被認為是奈米藥物輸送的多功能平台，因為它們能夠封裝多種分子並控制藥物釋放。 隨著該領域研究的不斷發展，圍繞 LNP 在藥物傳遞中的應用的智力資本也在不斷增長。

然而，脂質奈米顆粒的生產是一個複雜且成本密集的過程，需要多種專業知識。 因此，製藥公司越來越依賴專業的合約製造組織 (CMO)，這些組織擁有必要的技術和專業知識來解決其技術和營運挑戰。 透過外包給此類服務供應商，贊助商可以利用創新的 LNP 技術並獲得營運靈活性。 考慮到 LNP 的固有優勢（小尺寸、多功能特性和可定製表面），基於 LNP 的治療市場預計在短期內將顯著增長。 這種成長反過來將推動預測期內脂質奈米顆粒製造市場的擴大。

本報告分析了全球優質奈米粒子製造（服務和技術）市場，概述了優質奈米粒子、最新市場狀況、主要市場促進和限制因素以及整體市場規模趨勢。我們調查了前景、按細分市場和地區劃分的詳細趨勢、主要資本交易和業務聯盟的近期動向以及主要公司的概況。

市場主要參與者

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

目錄

第一章前言

第二章分析方法

第 3 章經濟與其他專案特定考量

第 4 章執行摘要

第 5 章簡介

  • 分析概述
  • 脂質概述
  • 脂質奈米顆粒概述
  • 與脂質奈米顆粒生產相關的挑戰
  • 需要外包脂質奈米顆粒的生產
  • 結論

第 6 章脂質奈米顆粒：服務供應商格局

  • 分析概述
  • 脂質奈米粒子製造：服務提供者列表

第七章脂質奈米顆粒：技術現況

  • 分析概述
  • 脂質奈米顆粒：技術現狀
  • 脂質奈米粒子技術：技術開發商名單

第 8 章其他類型的脂質：服務提供者格局

  • 分析概述
  • 其他類型的脂質：服務提供者列表

第九章企業競爭力分析

  • 分析概述
  • 先決條件與關鍵參數
  • 分析法
  • 脂質奈米顆粒製造服務商：公司競爭力分析

第10章技術競爭力分析

  • 分析概述
  • 先決條件與關鍵參數
  • 分析法
  • 脂質奈米粒子技術：競爭分析

第十一章公司簡介：脂質奈米顆粒服務商

  • 分析概述
  • Curia
  • Emergent BioSolutions
  • EUROAPI
  • Evonik
  • Ardena
  • BIOVECTRA
  • Company Overview
  • Precision NanoSystems

第十二章公司簡介：脂質奈米顆粒技術開發商

  • 分析概述
  • Ascendia Pharmaceuticals
  • leon-nanodrugs
  • Pantherna Therapeutics
  • TLC Biosciences
  • Acuitas Therapeutics
  • Integrated Nanotherapeutics
  • Matinas BioPharma

第 13 章公司簡介：其他類型的脂質服務提供者

  • 分析概述
  • Avanti Polar Lipids
  • Corden Pharma
  • Fujifilm
  • Merck
  • FormuMax Scientific
  • Creative Biolabs
  • Fresenius Kabi

第 14 章商業夥伴/合作

  • 分析概述
  • 業務夥伴模式
  • 脂質奈米粒子服務與技術：商業聯盟與合作列表

第 15 章可能的合作夥伴分析

  • 分析概述
  • 分析法
  • mRNA 藥物開發人員：北美潛在的策略夥伴
  • mRNA 藥物開發商：歐洲和亞太地區的潛在策略夥伴

第 16 章買還是買：決策架構

  • 分析概述
  • 先決條件與關鍵參數
  • 脂質奈米粒子服務提供者： "自製還是外購" 決策框架
  • 結論

第十七章產能分析

  • 分析概述
  • 重要假設與分析方法
  • 脂質奈米顆粒的合約製造能力已在世界各地推廣

第 18 章市場影響分析：驅動因素、限制、機會、挑戰

  • 分析概述
  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場挑戰
  • 結論

第十九章全球脂質奈米顆粒製造市場

  • 分析概述
  • 假設和分析方法
  • 全球脂質奈米顆粒製造市場：過去趨勢（2018-2022）與預測（2023-2035）
  • 主要市場細分

第 20 章脂質奈米顆粒製造市場：依脂質奈米顆粒類型劃分

  • 分析概述
  • 重要假設與分析方法
  • 脂質奈米顆粒製造市場：依脂質奈米顆粒類型劃分（2018年、2023年、2035年）
  • 數據測量與驗證

第 21 章脂質奈米顆粒製造市場，依提供的分子類型劃分

  • 分析概述
  • 重要假設與分析方法
  • 脂質奈米顆粒製造市場：依供應分子類型劃分（2018、2023、2035）
  • 數據測量與驗證

第 22 章脂質奈米顆粒製造市場：依公司規模劃分

  • 分析概述
  • 重要假設與分析方法
  • 脂質奈米顆粒製造市場：依公司規模劃分（2018、2023、2035）
  • 數據測量與驗證

第 23 章脂質奈米顆粒製造市場：依目標治療領域劃分

  • 分析概述
  • 重要假設與分析方法
  • 脂質奈米顆粒製造市場：依目標治療領域劃分（2018、2023、2035）
  • 數據測量與驗證

第 24 章脂質奈米顆粒製造市場：依最終用戶類型劃分

  • 分析概述
  • 重要假設與分析方法
  • 脂質奈米顆粒製造市場：依最終使用者類型劃分（2018、2023、2035）
  • 數據測量與驗證

第25章脂質奈米顆粒製造市場：依主要地區劃分

  • 分析概述
  • 重要假設與分析方法
  • 脂質奈米粒子製造市場：依主要地區劃分（2018、2023、2035）
  • 數據測量與驗證

第26章結論

第 27 章管理考量

  • 分析概述
  • LIPOSOMA
  • BIOVECTRA
  • OZ Biosciences

第 28 章附錄 1：表格資料

第29章附錄2：公司與組織名單

簡介目錄
Product Code: RA100461

The global lipid nanoparticle manufacturing market is valued at USD 0.66 billion in 2023 growing at a CAGR of 11.8% during the forecast period 2023-2035.

In recent years, the pharmaceutical industry has experienced significant expansion, evident in the increasing number of drugs undergoing approval or exploration in preclinical studies and clinical trials. However, a persistent hurdle in drug development lies in the poor water solubility and bioavailability of many compounds. Roughly 90% of drugs in development and nearly 40% of existing pharmacological products face challenges regarding solubility or permeability. These issues often lead to premature elimination from the body before they can be absorbed, impacting their effectiveness. Consequently, pharmaceutical firms are actively seeking solutions to overcome these obstacles. Among the various strategies to enhance the solubility and bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and similar lipid-based additives have attracted substantial attention from drug developers. LNPs are recognized as a versatile platform in nanomedicine delivery due to their capacity to encapsulate diverse molecules and offer controlled drug release. As research in this field flourishes, the intellectual capital concerning the use of LNPs in drug delivery has also expanded.

Yet, manufacturing lipid nanoparticles is a complex and cost-intensive process that demands diverse expertise. Thus, pharmaceutical companies increasingly rely on specialized contract manufacturing organizations (CMOs) equipped with the necessary technology and know-how to tackle technical and operational challenges. Outsourcing to such service providers allows sponsors to tap into innovative LNP technologies and gain operational flexibility. Given the inherent advantages of LNPs-small size, multifunctional properties, and customizable surfaces-the market for LNP-based therapeutics is poised for significant growth in the foreseeable future. This growth will consequently drive expansion in the lipid nanoparticle manufacturing market during the projected period.

Key Market Segments:

Type of Lipid Nanoparticle

  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers

Type of Molecule Delivered

  • Nucleic Acids
  • Small Molecules
  • Peptides/ Proteins
  • Others

Company Size

  • Very Large and Large
  • Mid-sized
  • Small

Therapeutic Area

  • Infectious Diseases
  • Oncological Disorders
  • Blood Disorders
  • Rare Diseases
  • Other Disorders

Type of End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Other End-users

Key Geographical Regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the lipid nanoparticle manufacturing market based on type of lipid nanoparticle, type of molecule delivered, company size, target therapeutic area, type of end-user and key geographical regions
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • Comprehensive methodology adopted for the study, encompassing assumptions, methodologies, and quality control measures for accuracy and reliability of findings.
  • Historical trends, currency fluctuations, foreign exchange impact, recession, and inflation measurements shaping the lipid nanoparticle manufacturing market.
  • High-level overview capturing current state and potential evolution of the lipid nanoparticle manufacturing market in the medium to long term.
  • Exploration of lipids, their types, advantages, applications in pharmaceuticals, challenges in formulation, and the rising need for outsourcing manufacturing operations.
  • Evaluation based on establishment year, company size, headquarters location, manufacturing facility location, operational scale, delivered molecule types, therapeutic areas, and additional services offered.
  • Evaluation based on formulation methods, molecule types, compatible dosage forms, administration routes, therapeutic areas, establishment year, company size, headquarters location, business models, and active players.
  • Examination based on establishment year, company size, headquarters location, manufacturing facilities, operational scale, lipid types, product types, additional services offered, and competitiveness analysis.
  • Comparative assessment of lipid nanoparticle contract manufacturing organizations based on company strength, service strength, and the number of manufacturing facilities.
  • Insightful analysis based on developer strength, technology aspects, and applicability in therapeutic areas.
  • Detailed profiles of key players in LNP manufacturing services and technology, featuring company overview, portfolios, recent developments, and future outlook.
  • Examination of partnerships between stakeholders since 2019, based on various parameters and regional distribution of involved companies.
  • Evaluation of mRNA vaccine and therapeutics developers for potential partnerships with lipid nanoparticle manufacturers, considering multiple criteria.
  • Detailed exploration of factors influencing the decision of companies to outsource LNP manufacturing or develop in-house capabilities.
  • Analysis of global installed capacity among LNP contract manufacturers based on company size, operational scale, and geographical distribution.
  • Identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges impacting lipid nanoparticle manufacturing market growth.

Key Benefits of Buying this Report:

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the lipid nanoparticle manufacturing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Inclusions and Exclusions
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Lipids
  • 5.3 Introduction to Lipid Nanoparticles
    • 5.3.1. Types of Lipid Nanoparticles
      • 5.3.1.1. Solid Lipid Nanoparticles
      • 5.3.1.2. Nanostructured Lipid Carriers
    • 5.3.2. Advantages of Lipid Nanoparticles
    • 5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
      • 5.3.3.1. Cancer Treatment
      • 5.3.3.2. Gene Therapy
      • 5.3.3.3. Vaccine Development
      • 5.3.3.4. Medical Imaging / Diagnostics
      • 5.3.3.5. Additional Applications
  • 5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
  • 5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
  • 5.6. Concluding Remarks

6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
    • 6.2.1 Analysis by Year of Establishment
    • 6.2.2 Analysis by Company Size
    • 6.2.3 Analysis by Location of Headquarters
    • 6.2.4 Analysis by Company Size and Location of Headquarters
    • 6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
    • 6.2.6 Analysis by Scale of Operation
    • 6.2.7 Analysis by Type of Molecule Delivered
    • 6.2.8 Analysis by Therapeutic Area
    • 6.2.9 Analysis by Type of Additional Services Offered

7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Lipid Nanoparticle: Technology Landscape
    • 7.2.1. Analysis by Type of Formulation Method
    • 7.2.2. Analysis by Type of Molecule Delivered
    • 7.2.3. Analysis by Compatible Dosage Form
    • 7.2.4. Analysis by Routes of Administration
    • 7.2.5. Analysis by Therapeutic Area
  • 7.3. Lipid Nanoparticle Technologies: List of Technology Developers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Company Size and Location of Headquarters
    • 7.3.5. Analysis by Business Model
    • 7.3.6. Most Active Players: Analysis by Number of Technologies

8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Other Types of Lipids: List of Service Providers
    • 8.2.1 Analysis by Year of Establishment
    • 8.2.2 Analysis by Company Size
    • 8.2.3 Analysis by Location of Headquarters
    • 8.2.4 Analysis by Company Size and Location of Headquarters
    • 8.2.5. Analysis by Location of Manufacturing Facility
    • 8.2.6. Analysis by Scale of Operation
    • 8.2.7 Analysis by Type of Lipid Manufactured
    • 8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
    • 8.2.9. Analysis by Type of Product
    • 8.2.10. Analysis by Type of Additional Services Offered
    • 8.2.11. Analysis by Type of Product and Type of Additional Services Offered

9. COMPANY COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
  • 9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
    • 9.4.1. Company Competitiveness Analysis: Small Players
    • 9.4.2. Company Competitiveness Analysis : Mid-sized Players
    • 9.4.3. Company Competitiveness Analysis : Large and Very Large Players

10. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Key Parameters
  • 10.3. Methodology
  • 10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
    • 10.4.1. Technology Competitiveness Analysis: Players based in North America
    • 10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific

11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES

  • 11.1. Chapter Overview
  • 11.2. Curia
    • 11.2.1. Company Overview
    • 11.2.2. Service Portfolio
    • 11.2.3. Recent Developments and Future Outlook
  • 11.3. Emergent BioSolutions
    • 11.3.1. Company Overview
    • 11.3.2. Service Portfolio
    • 11.3.3. Recent Developments and Future Outlook
  • 11.4. EUROAPI
    • 11.4.1. Company Overview
    • 11.4.2. Service Portfolio
    • 11.4.3. Recent Developments and Future Outlook
  • 11.5. Evonik
    • 11.5.1. Company Overview
    • 11.5.2. Service Portfolio
    • 11.5.3. Recent Developments and Future Outlook
  • 11.6. Ardena
    • 11.6.1. Company Overview
    • 11.6.2. Service Portfolio
  • 11.7. BIOVECTRA
  • 117.1. Company Overview
    • 11.7.2. Service Portfolio
  • 11.8. Precision NanoSystems
    • 11.8.1. Company Overview
    • 11.8.2. Service Portfolio

12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS

  • 12.1. Chapter Overview
  • 12.2. Ascendia Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Lipid Nanoparticle Technology Portfolio
    • 12.2.3. Recent Developments and Future Outlook
  • 12.3. leon-nanodrugs
    • 12.3.1. Company Overview
    • 12.3.2. Lipid Nanoparticle Technology Portfolio
    • 12.3.3. Recent Developments and Future Outlook
  • 12.4. Pantherna Therapeutics
    • 12.4.1. Company Overview
    • 12.4.2. Lipid Nanoparticle Technology Portfolio
    • 12.4.3. Recent Developments and Future Outlook
  • 12.5. TLC Biosciences
    • 12.5.1. Company Overview
    • 12.5.2. Lipid Nanoparticle Technology Portfolio
    • 12.5.3. Recent Developments and Future Outlook
  • 12.6. Acuitas Therapeutics
    • 12.6.1. Company Overview
    • 12.6.2. Service Portfolio
  • 12.7. Integrated Nanotherapeutics
    • 12.7.1. Company Overview
    • 12.7.2. Service Portfolio
  • 12.8. Matinas BioPharma
    • 12.8.1. Company Overview
    • 12.8.2. Service Portfolio

13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS

  • 13.1. Chapter Overview
  • 13.2. Avanti Polar Lipids
    • 13.2.1. Company Overview
    • 13.2.2. Service Portfolio
    • 13.2.3. Recent Developments and Future Outlook
  • 13.3. Corden Pharma
    • 13.3.1. Company Overview
    • 13.3.2. Service Portfolio
    • 13.3.3. Recent Developments and Future Outlook
  • 13.4. Fujifilm
    • 13.4.1. Company Overview
    • 13.4.2. Service Portfolio
    • 13.4.3. Recent Developments and Future Outlook
  • 13.5. Merck
    • 13.5.1. Company Overview
    • 13.5.2. Service Portfolio
    • 13.5.3. Recent Developments and Future Outlook
  • 13.6. FormuMax Scientific
    • 13.6.1. Company Overview
    • 12.6.2. Service Portfolio
  • 13.7. Creative Biolabs
    • 13.7.1. Company Overview
    • 13.7.2. Service Portfolio
  • 13.8. Fresenius Kabi
    • 13.8.1. Company Overview
    • 13.8.2. Service Portfolio

14. PARTNERSHIPS AND COLLABORATIONS

  • 14.1. Chapter Overview
  • 14.2. Partnership Models
  • 14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
    • 14.3.1. Analysis by Year of Partnership
    • 14.3.2. Analysis by Type of Partnership
    • 14.3.3. Analysis by Year and Type of Partnership
    • 14.3.4. Analysis by Type of Molecule
    • 14.3.5. Analysis by Therapeutic Area
    • 14.3.6. Analysis by Type of Partner
    • 14.3.7. Most Active Players: Analysis by Number of Partnerships
    • 14.3.8. Analysis by Geography
      • 14.3.8.1. Intracontinental and Intercontinental Deals
      • 14.3.8.2. International and Local Deals

15. LIKELY PARTNER ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Methodology
  • 15.2. mRNA Drug Developers: Potential Strategic Partners in North America
  • 15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific

16. MAKE VERSUS BUY DECISION FRAMEWORK

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Key Parameters
  • 16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
    • 16.3.1. Scenario 1
    • 16.3.2. Scenario 2
    • 16.3.3. Scenario 3
    • 16.3.4. Scenario 4
  • 16.4. Concluding Remarks

17. CAPACITY ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
    • 17.3.1. Analysis by Range of Installed Capacity
    • 17.3.2. Analysis by Company Size
    • 17.3.3. Analysis by Scale of Operation
    • 17.3.4. Analysis by Location of Manufacturing Facility
      • 17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
      • 17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
      • 17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
    • 17.3.5. Concluding Remarks

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 18.1. Chapter Overview
  • 18.2. Market Drivers
  • 18.3. Market Restraints
  • 18.4. Market Opportunities
  • 18.5. Market Challenges
  • 18.6. Conclusion

19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 19.3.1. Scenario Analysis
      • 19.3.1.1. Conservative Scenario
      • 19.3.1.2. Optimistic Scenario
  • 19.4. Key Market Segmentations

20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
    • 20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.7. Data Triangulation and Validation

21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
    • 21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.4. Data Triangulation and Validation

22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
    • 22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.4. Data Triangulation and Validation

23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
    • 23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 23.4. Data Triangulation and Validation

24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
    • 24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 24.4. Data Triangulation and Validation

25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
    • 25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 25.4. Data Triangulation and Validation

26. CONCLUSION

27. EXECUTIVE INSIGHTS

  • 27.1. Chapter Overview
  • 27.2. LIPOSOMA
    • 27.2.1. Company Snapshot
  • 27.3. BIOVECTRA
    • 27.3.1. Company Snapshot
  • 27.4. OZ Biosciences
    • 27.4.1. Company Snapshot

28. APPENDIX 1: TABULATED DATA

29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION